Ectodomain shedding of PLA2R1 is mediated by the metalloproteases ADAM10 and ADAM17.

ADAM10 ADAM17 PLA2R1 inflammation membranous nephropathy metalloproteases podocyte shedding soluble PLA2R1

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
17 Jun 2024
Historique:
received: 03 12 2023
revised: 17 05 2024
accepted: 30 05 2024
medline: 20 6 2024
pubmed: 20 6 2024
entrez: 19 6 2024
Statut: aheadofprint

Résumé

Phospholipase A2 receptor 1 (PLA2R1) is a 180-kDa transmembrane protein that plays a role in inflammation and cancer, and is the major autoantigen in membranous nephropathy (MN), a rare but severe autoimmune kidney disease. A soluble form of PLA2R1 has been detected in mouse and human serum. It is likely produced by proteolytic shedding of membrane-bound PLA2R1 but the mechanism is unknown. Here, we show that human PLA2R1 is cleaved by A Disintegrin And Metalloprotease 10 (ADAM10) and ADAM17 in HEK293 cells, mouse embryonic fibroblasts and human podocytes. By combining site-directed mutagenesis and sequencing, we determined the exact cleavage site within the extracellular juxtamembrane stalk of human PLA2R1. Orthologs and paralogs of PLA2R1 are also shed. By using pharmacological inhibitors and genetic approaches with RNA interference and knock-out cellular models, we identified a major role of ADAM10 in the constitutive shedding of PLA2R1, and a dual role of ADAM10 and ADAM17 in the stimulated shedding. We did not observe evidence for cleavage by β- or γ-secretase, suggesting that PLA2R1 may not be a substrate for Regulated Intramembrane Proteolysis. PLA2R1 shedding occurs constitutively and can be triggered by the calcium ionophore ionomycin, the protein kinase C inducer PMA, cytokines and lipopolysaccharides, in vitro and in vivo. Altogether, our results show that PLA2R1 is a novel substrate for ADAM10 and ADAM17, producing a soluble form that is increased in inflammatory conditions and likely exerts various functions in physiological and pathophysiological conditions including inflammation, cancer and MN.

Identifiants

pubmed: 38897568
pii: S0021-9258(24)01981-1
doi: 10.1016/j.jbc.2024.107480
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107480

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Guillaume Dolla (G)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France.

Sarah Nicolas (S)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France.

Ligia Ramos Dos Santos (LR)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Laboratoire d'Excellence DistALZ, Sophia Antipolis, Valbonne, France.

Alexandre Bourgeois (A)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Laboratoire d'Excellence DistALZ, Sophia Antipolis, Valbonne, France.

Raphaëlle Pardossi-Piquard (R)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Laboratoire d'Excellence DistALZ, Sophia Antipolis, Valbonne, France.

Franck Bihl (F)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France.

Christelle Zaghrini (C)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France.

Joana Justino (J)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France.

Christine Payré (C)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France.

Pascal Mansuelle (P)

Plateforme de Protéomique de l'Institut de Microbiologie de la Méditerranée (IMM), Marseille Protéomique (MaP), Aix Marseille Université (AMU), Centre National de la Recherche Scientifique (CNRS) FR3479, 31 Chemin Joseph Aiguier, 13009 Marseille, France.

Christoph Garbers (C)

Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.

Pierre Ronco (P)

Institut National de la Santé et de la Recherche Médicale (INSERM), UMR-S1155, Paris, France; Sorbonne Université, Université Pierre et Marie Curie Paris 06, Paris, France.

Frédéric Checler (F)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Laboratoire d'Excellence DistALZ, Sophia Antipolis, Valbonne, France.

Gérard Lambeau (G)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France. Electronic address: lambeau@ipmc.cnrs.fr.

Agnès Petit-Paitel (A)

Université Côte d'Azur (UniCa), Centre National de la Recherche Scientifique, Inserm, Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France. Electronic address: apetit@ipmc.cnrs.fr.

Classifications MeSH